Everything below concerns MOD GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Alexei Sayle (born 7 August 1952), English actor, author, stand-up comedian, television presenter and former recording artist; voted the 18th greatest stand-up comic of all time on Channel 4's 100 Greatest Stand-Ups in 2007; In an updated 2010 poll he came 72nd. has written two short story collections, five novels, including a graphic novel and a radio series spin-off book, as well as columns for various publications; has written for Time Out and the Sunday Mirror; was one of eight contributory authors to the BBC Three competition End of Story. Simon Schama (born 13 February 1945), author of Lithuanian Jewish ancestry, specialising in art history, Dutch history, Jewish history, and French history. He is a University Professor of History and Art History at Columbia University, New York. Isaac Schapera FBA FRAI (23 June 1905 Garies, Cape Colony – 26 June 2003 London, England); of South African Jewish-Russian Jewish ancestry; author of numerous highly regarded anthropology books and over 200 monographs and scholarly academic papers on Africa;social anthropologist at London School of Economics specialising in South Africa; notable for his ethnographic and typological studies of the indigenous peoples of Botswana and South Africa; one of the founders of group that would develop British social anthropology, and students included important figures of anthropology, such as Ernest Gellner, Eileen Krige, Hilda Kuper, Max Gluckman, John Comaroff, Johan Frederik Holleman and Jean Comaroff.
==== Blood-cell formation ==== The specificity of the human immune-cell repertoire is what allows the human body to defend itself from rapidly adapting antigens. However, the immune system is vulnerable to degradation upon the pathogenesis of disease, and because of the critical role that it plays in overall defense, its degradation is often fatal to the organism as a whole. Diseases of hematopoietic cells are diagnosed and classified via a subspecialty of pathology known as hematopathology. The specificity of the immune cells is what allows recognition of foreign antigens, causing further challenges in the treatment of immune disease. Identical matches between donor and recipient are no longer required for successful transplantation. Rather, haploidentical matches have facilitated numerous transplants, given improvements in post-transplant immunosuppressive regimens. Research using both hematopoietic adult stem cells and embryonic stem cells has provided insight into the possible mechanisms and methods of treatment for many of these ailments. Fully mature human red blood cells may be generated ex vivo by hematopoietic stem cells (HSCs), which are precursors of red blood cells. In this process, HSCs are grown together with stromal cells, creating an environment that mimics the conditions of bone marrow, the natural site of red-blood-cell growth. Erythropoietin, a growth factor, is added, coaxing the stem cells to complete terminal differentiation into red blood cells.
=== Pollutants === Storage in metal cabinets is the best material to maintain herbaria collections. Metal cabinets do not release volatile organic compounds as wooden cabinets do. The metal shelves can be easily cleaned and a well-sealed cabinet will provide a stable microclimate for the specimen.
== See also == Politics in the United Kingdom 2020s in United Kingdom political history 2023 in United Kingdom politics and government Timeline of the COVID-19 pandemic in the United Kingdom (2023) 2023 in British music 2023 in British television 2023 in British radio List of British films of 2023
=== Structural proteomics === Structural proteomics includes the analysis of protein structures at large-scale. It compares protein structures and helps identify functions of newly discovered genes. The structural analysis also helps to understand that where drugs bind to proteins and also shows where proteins interact with each other. This understanding is achieved using different technologies such as X-ray crystallography and NMR spectroscopy.
Sources: en.wikipedia.org
=== Tolerance dose === In 1931, the U.S. Advisory Committee on X-Ray and Radium Protection (ACXRP, now the National Council on Radiation Protection and Measurements, NCRP), founded in 1929, published the results of a study on the so-called tolerance dose, on which a scientifically based radiation protection guideline was based. Exposure limits were gradually lowered. In 1936 the tolerance dose was 0.1 R/day. The unit "R" (the X-ray) from the CGS unit system has been obsolete since the end of 1985. Since then, the SI unit of ion dose has been "coulomb per kilogram".
=== Addison's Disease === Corticotropic cells can also be the cause of Addison's disease in some instances. Addison's disease is characterized adrenal insufficiency, which is defined as the underproduction of glucocorticoids by the adrenal cortex. If the corticotropes underproduce ACTH this can result in secondary adrenal insufficiency, causing the adrenal glands to underproduce cortisol. This can be caused by tumors of the anterior pituitary or hypothalamus, inflammation, or surgery. This ultimately results in the underproduction of cortisol, which has many detrimental symptoms. Symptoms of Addison's disease include:
=== Flours === Functional flours are produced from specific cereal variety (wheat, maize, rice or other) conjugated to specific heat treatment able to increase stability, consistency and general functionalities. These functional flours are resistant to industrial stresses such as acidic pH, sterilisation, freeze conditions, and can help food industries to formulate with natural ingredients. For the final consumer, these ingredients are more accepted because they are shown as "flour" in the ingredient list. Flour is often used for thickening gravies, gumbos, and stews. The most basic type of thickening agent, flour blended with water to make a paste, is called whitewash. It must be cooked in thoroughly to avoid the taste of uncooked flour. Roux, a mixture of flour and fat (usually butter) cooked into a paste, is used for gravies, sauces and stews. Cereal grains (oatmeal, couscous, farina, etc.) are used to thicken soups. Yogurt is popular in Eastern Europe and Middle East for thickening soups. Soups can also be thickened by adding grated starchy vegetables before cooking, though these will add their own flavour. Tomato puree also adds thickness as well as flavour. Egg yolks are a traditional sauce thickener in professional cooking; they have rich flavor and offer a velvety smooth texture but achieve the desired thickening effect only in a narrow temperature range. Overheating easily ruins such a sauce, which can make egg yolk difficult to use as a thickener for amateur cooks. Other thickeners used by cooks are nuts (including rehan) or glaces made of meat or fish.
==== Absorption ==== The absorption of atomoxetine with oral administration is rapid and complete. The drug's absolute bioavailability is 63 to 94%. This is moderated by first-pass metabolism and CYP2D6 status, with poor metabolizers having a bioavailability of 94% and extensive metabolizers having a bioavailability of 63%. Extensive metabolizers are considered to have normal CYP2D6 activity and constitute >90% of people, while poor metabolizers constitute a small minority of up to 7%. The bioavailability of atomoxetine is not different between capsule and solution forms. The time to peak levels of atomoxetine is 1 to 2 hours. It has been reported that the time to peak levels was 1.0 hours in CYP2D6 extensive metabolizers and 2.5 hours in CYP2D6 poor metabolizers. Taking atomoxetine with food does not affect its bioavailability or total exposure but decreases peak levels by 9% with a typical meal and 37% with a standard high-fat breakfast. In addition, food delays the time to peak levels by 3 hours. Atomoxetine exposure increases proportionally with higher doses over a range of 10 to 120 mg orally. Exposure to atomoxetine is proportional to body weight, and hence weight-normalizing dosing is required to produce equivalent exposure. In CYP2D6 poor metabolizers, atomoxetine peak levels are 5- to 6-fold higher and total exposure is 8- to 10-fold higher than in CYP2D6 extensive metabolizers.
=== Therapeutic insights === The distinct structure of RAGE makes it a potential target for therapeutic intervention, particularly in conditions involving chronic inflammation. Inhibitors that prevent ligand binding to the V domain have been studied to reduce downstream inflammatory signaling. Targeting the cytoplasmic domain to disrupt intracellular signal transduction is another approach being explored. Additionally, increasing the levels of sRAGE could serve as an effective strategy to neutralize pro-inflammatory ligands and limit their interaction with mRAGE, offering potential benefits in treating inflammatory conditions.
Sources: en.wikipedia.org
== Medical uses == Medications based on incretins are used in the treatment of type 2 diabetes mellitus as well as the management of obesity. Most of the earliest incretin-targeting agents to be approved fell into the class of DPP-4 inhibitors; these inhibit DPP-4 and prevent the enzymatic degradation of GLP-1 and GIP. The first medication in this class, sitagliptin, received FDA approval in 2006 for the treatment of type 2 diabetes. GLP-1 analogs principally act as agonists of the GLP-1 receptor and are thus insulinotropic. Exenatide was the first drug in this class to be used in the treatment of type 2 diabetes; it received FDA approval in 2005. More recently, longer-acting and more potent GLP-1 analogs have been developed, most notably semaglutide, which received FDA approval for type 2 diabetes in 2017. It was subsequently approved for the management of obesity. In 2021, it was in the Top 100 most-prescribed drugs in the United States. Tirzepatide (sold as Mounjaro and Zepbound) is a potent GIP analog with agonist activity at GIP and GLP-1 receptors. It was approved for the treatment of type 2 diabetes in the United States in May 2022, and for the management of obesity in November 2023.
=== Diagnosis and assessment === The assessment of riboflavin status is essential for confirming cases with non-specific symptoms whenever deficiency is suspected. Total riboflavin excretion in healthy adults with normal riboflavin intake is about 120 micrograms per day, while excretion of less than 40 micrograms per day indicates deficiency. Riboflavin excretion rates decrease as a person ages, but increase during periods of chronic stress and the use of some prescription drugs. Indicators used in humans are erythrocyte glutathione reductase (EGR), erythrocyte flavin concentration and urinary excretion. The erythrocyte glutathione reductase activity coefficient (EGRAC) provides a measure of tissue saturation and long-term riboflavin status. Results are expressed as an activity coefficient ratio, determined by enzyme activity with and without the addition of FAD to the culture medium. An EGRAC of 1.0 to 1.2 indicates that adequate amounts of riboflavin are present; 1.2 to 1.4 is considered low, greater than 1.4 indicates deficient. For the less sensitive "erythrocyte flavin method", values greater than 400 nmol/L are considered adequate and values below 270 nmol/L are considered deficient. Urinary excretion is expressed as nmol of riboflavin per gram of creatinine. Low is defined as in the range of 50 to 72 nmol/g. Deficient is below 50 nmol/g. Urinary excretion load tests have been used to determine dietary requirements.
Pyroglutamate aminopeptidase is a type of enzyme that cleaves the peptide bond linking the N-terminal end of a polypeptide forming a cyclical lactam to the next amino acid residue. This cyclic structure protects the polypeptide from degradation but renders the protein difficult to analyze in the laboratory. Pyroglutamate aminopeptidase may be used to cleave the cyclical lactam and will therefore leave the next amino acid with a free N-terminal.
== Medical uses == Amodiaquine has become an important drug in the combination therapy for malaria treatment in Africa. It is often used in combination with artesunate as a by mouth artemisinin-based combination therapy (ACT) for uncomplicated P. falciparum malaria. Amodiaquine has also been found to work against chloroquine-resistant P. falciparum strains of malaria, though there is geographic variation in its activity against chloroquine-resistant strains. It is also used in combination with sulfadoxine/pyrimethamine.
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.